Event

Separate registration required.

As the cost of bringing a new health technology to market continues to climb, more and more firms, developers, and investors are searching for tools to prioritize their efforts on the technologies with the greatest potential for clinical impact and market viability. While health economic analysis has long been established as a necessity to inform decision making for market access and reimbursement, it is increasingly being used at earlier stages of product development for healthcare and life sciences to increase the access rate of R&E and efficiently prioritize data collection. The number of available methods for this field has continued to expand.

This course aims to demystify the objectives of early-stage health technology assessment and the methods of translational health economics. Students in the course will gain a thorough understanding of available methods for early-stage technology assessment, the specific challenges and solutions, and a clear sense of how to implement this in the complexity of health technology development, funding, regulation, pricing, and reimbursement. The course will utilize real-world examples and students will have the opportunity to strategize about the creation of a research plan for their purposes.

PREREQUISITE: Familiarity with key elements, methods, language, and basic health technology principles are prerequisites to attending this course.

Deputy Chief Executive

Office of Health Economics

London, England, UK

Managing Director

Washington Research Foundation

Seattle, WA, USA

Senior Manager-Global Market Access & Value Strategy

W. L. Gore & Associates, Inc.

Flagstaff, AZ, USA